Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab SC Retreatment in Multiple Myeloma
NCT03871829Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started May 2019; status: terminated.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03871829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03871829.